

SENTINEL ARTICLES IN GYNECOLOGIC CANCER

Uterine Carcinosarcoma and Leiomyosarcoma

Disclaimer: This list represents a collection of articles identified by members of SGO as important in the context of specific disease sites, it is not meant to serve as a specific tool of study for examinations and has not been approved by governing organizations in education

1. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. -cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus. *Gynecol Oncol.* 2007;107(2):177–185.
<https://pubmed.ncbi.nlm.nih.gov/17822748/>
2. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 2007;25(5):526–531. <https://pubmed.ncbi.nlm.nih.gov/17290061/>
3. Leitao MM, Sonoda Y, Brennan MF, et al. Incidence of lymph node and ovarian metastasis in leiomyosarcoma of the uterus. *Gynecol Oncol.* 2003;91(1):209–212.
<https://pubmed.ncbi.nlm.nih.gov/14529683/>
4. Giuntoli RL II, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. *Gynecol Oncol.* 2003;89(3):460–469. <https://pubmed.ncbi.nlm.nih.gov/12798712/>
5. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcoma: emphasis on impact of lymphadenectomy and oophorectomy. *Cancer.* 2008;112(4):820–830. <https://pubmed.ncbi.nlm.nih.gov/18189292/>
6. Goff BA, Rice LW, Fleischhaker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. *Gynecol Oncol.* 1993;50(1):105–109.
<https://pubmed.ncbi.nlm.nih.gov/8349151/>

7. O’Cearbhaill R, Hensley ML. Optimal management of uterine leiomyosarcoma. *Expert Rev Anticancer Ther.* 2010;10(2):153–169. <https://pubmed.ncbi.nlm.nih.gov/20131992/>
8. Levenback C, Rubin SC, McCormack PM, et al. Resection of pulmonary metastases from uterine sarcomas. *Gynecol Oncol.* 1992;45(2):202–205. <https://pubmed.ncbi.nlm.nih.gov/1592288/>
9. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma: hormonal aspects. *Gynecol Oncol.* 2003;90(1):170–176. <https://pubmed.ncbi.nlm.nih.gov/12821359/>
10. Hensley, M. L., Ishill, N., Soslow, R., Larkin, J., Abu Rustum, N., Sabbatini, P., ... Aghajanian, C. A. (2009). Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. *Gynecologic oncology*, 112(3), 563-567. <https://pubmed.ncbi.nlm.nih.gov/19135708/>
11. Powell, M. A., Filiaci, V. L., Rose, P. G., Mannel, R. S., Hanjani, P., Degeest, K., ... Ueland, F. R. (2010). Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. *Journal of clinical oncology*, 28(16), 2727-2731. <https://pubmed.ncbi.nlm.nih.gov/20421537/>
12. Kanthan, R., Senger, J. (2011). Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. *Obstetrics and Gynecology International*, 2011, 470795-470795. <https://pubmed.ncbi.nlm.nih.gov/22007228/>
13. Cantrell, L. A., Havrilesky, L., Moore, D. T., O’Malley, D., Liotta, M., Secord, A. A., ... Gehrig, P. A. (2012). A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. *Gynecologic oncology*, 127(1), 22-26. <https://pubmed.ncbi.nlm.nih.gov/22727985/>
14. George, S., Feng, Y., Manola, J., Nucci, M. R., Butrynski, J. E., Morgan, J. A., ... Krasner, C. (2014). Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. *Cancer*, 120(5), 738-743. <https://pubmed.ncbi.nlm.nih.gov/24222211/>

15. Hensley, M. L., Patel, S. R., von Mehren, M., Ganjoo, K., Jones, R. L., Staddon, A., ... Demetri, G. D. (2017). Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. *Gynecologic oncology*, 146(3), 531-537.
<https://pubmed.ncbi.nlm.nih.gov/28651804/>
16. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. *Lancet Oncol*. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4. PMID: 28882536 [GeDDiS trial] <https://pubmed.ncbi.nlm.nih.gov/28882536/>